Cord Blood News Volume 5.40 | Oct 10 2013

Umbilical Cord Blood Transplantation from Unrelated Donors in Patients with PH-Positive Acute Lymphoblastic Leukemia
Researchers report the outcome of 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia underwent myeloablative single unit cord blood transplantation from unrelated donors within the GETH/GITMO cooperative group. [Haematologica] Abstract | Full Article

Amniotic Fluid Stem Cells with Low γ-Interferon Response Showed Behavioral Improvement in Parkinsonism Rat Model
To further investigate the properties of amniotic fluid stem cells (AFSCs) for translational applications, investigators examined the cell surface expression of human leukocyte antigens of these cells and estimated the therapeutic effect of AFSCs in parkinsonian rats. [PLoS One] Full Article

Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms
Scientists compared the clinical outcomes of adults with acute leukemia that received single-unit umbilical cord blood transplantation (UCBT) after conditioning with a busulfan/antithymocyte globulin-based regimen at or double-unit UCBT after conditioning with a total body irradiation-based regimen. [Biol Blood Marrow Transpl] Abstract

mRNAs and miRNAs Profiling of Mesenchymal Stem Cells Derived from Amniotic Fluid and Skin: The Double Face of the Coin
Researcher report not only the isolation and the traditional characterization of mesenchymal stem cells derived from amniotic fluid and skin but also a molecular characterization based on mRNAs and miRNAs profiling. [Cell Tissue Res] Abstract

Co-Transplantation of Mesenchymal Stromal Cells and Cord Blood Cells in Treatment of Diabetes
Researchers investigated whether co-transplantation of umbilical cord-derived mesenchymal stromal cells and cord blood mononuclear cells could reverse hyperglycemia in type 1 diabetic mice and aimed to determine the appropriate ratio for co-transplantation. [Cytotherapy] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Geron Completes Divestiture of Stem Cell Assets
Geron Corporation announced the closing of the transaction to divest the company’s stem cell assets. Geron entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc. [Geron Corporation] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Postdoctoral Position – Patient-Specific Stem Cell Lines: Disease Modeling, Repair and Transplantation (Columbia University)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Postdoctoral Position – Immune Recovery after Hematopoietic Stem Cell Transplantation (University of Minnesota – Twin Cities)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Research Associate – Leukemia & Stem Cell Biology (King’s College London)

Postdoctoral Fellow – Differentiation of Erythrocytes and Endothelial Cells from Hemangioblast (University of Rochester)

Stem Cell Biology Researcher – Human Genetics and Stem Cell Biology (The Czech Genetic Bank Ltd.)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.